Fulcrum Therapeutics Inc (FULC) — Titan Protect Analysis

FULC

Fulcrum Therapeutics Inc

Healthcare · ·

$3.69

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$215M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.27

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-27.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.50

+456% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 10 analysts covering this stock

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Fa

https://www.fulcrumtx.com

Country: United States Employees: 55 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.124

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0106

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.481

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-37.8%

Historical annualised return based on price data

Max Drawdown

-78.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

3.01

Significantly more volatile than the market

52W High

$15.74

77% below the year high

52W Low

$2.83

30% above the year low

Avg Volume

1,410,407

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.15

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.76

Meaningful debt load — monitor closely

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-37,739,000

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-76,116,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$25.00

Target Median

$20.50

Target Low

$8.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go